In spite of the small sample size, we found that the circulating MCT1+CD9+ EVs in the serum reflected the tumor burden or treatment response in vivo, indicating the potential for the translation of this liquid biopsy into clinics for the management of SS. The gene discussed is SLC16A1; the disease is neoplasm.